Kos Biotechnology Partners Invests in Golden Age Health to Expand Rare Disease Therapy Access
Kos Biotechnology Partners has announced a strategic investment in Golden Age Health (GAH) through its inaugural fund, Kos BioVentures. The partnership aims to accelerate the commercialization of approved and near-approved rare disease medicines across Greater China, Southeast Asia, and the Gulf regions. The investment is intended to scale GAH's commercial infrastructure and portfolio within the Asia-Pacific market while facilitating a cross-border exchange of biotech innovation between Western markets and Asia. As part of the deal, Kos Managing Partner Alex Tzoukas will join the Golden Age Health Board of Directors. Golden Age Health, chaired by former Biogen CEO Michel Vounatsos, focuses on navigating complex regulatory landscapes to bring specialty pharmaceuticals to underserved populations. The collaboration leverages Kos's transatlantic network and institutional backing from entities like the Hellenic Development Bank of Investments.
Tickers: $BIIB
Topics: biotechnology board appointment expansion pharmaceuticals strategic investment